Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Irritability is not a molecule, receptor, or canonical therapeutic target. Instead, it is a behavioral and affective state characterized by an increased tendency to respond to stimuli with negative emotions such as anger or frustration[1][4][7]. In biology and psychiatry, irritability refers broadly to the excitatory ability of living organisms—especially humans—to react to changes in their environment. It can manifest as mood disturbances and temper outbursts and is considered both a normal physiological reaction and an abnormal pathological sensitivity depending on context[1][4][7]. From a neurobiological perspective, irritability involves complex neural circuits including prefrontal areas (involved in inhibitory control), cortico-subcortical systems for reward processing (especially under frustration), and threat/arousal processing networks[1][5][7]. Neurotransmitter imbalances—particularly involving serotonin, dopamine, and GABA—are implicated in the regulation of irritability but are not themselves direct targets named “irritability”[2][8]. Clinically, irritability is recognized as an important transdiagnostic symptom across many psychiatric conditions such as mood disorders (e.g., depression, bipolar disorder), anxiety disorders, autism spectrum disorder (as part of diagnostic criteria), disruptive mood dysregulation disorder, oppositional defiant disorder, among others[1][5]. Treatments that may reduce irritability include psychotherapy (such as cognitive-behavioral therapy) and pharmacologic agents targeting neurotransmitter systems; however there are no drugs that directly interact with “irritability” itself because it is not a discrete molecular entity or receptor[5][7]. In summary: > Irritability should be classified as a clinical/behavioral phenomenon, not as a druggable molecular target. There are no canonical abbreviations or interacting drugs specific for “irritability,” nor does it fit into standard molecular classification families like receptors or enzymes. If you require information about specific molecules/receptors involved in the biological basis of irritability—such as serotonin transporter (SERT), dopamine receptors (DRD2/DRD4), GABA-A receptor—or wish to map symptoms like irritability onto known drug targets for research purposes, please specify which underlying pathway or molecule you want detailed information about.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Irritability.